GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Madrigal Pharmaceuticals Inc (FRA:YDO1) » Definitions » Shiller PE Ratio

Madrigal Pharmaceuticals (FRA:YDO1) Shiller PE Ratio : (As of May. 06, 2025)


View and export this data going back to 2007. Start your Free Trial

What is Madrigal Pharmaceuticals Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Madrigal Pharmaceuticals Shiller PE Ratio Historical Data

The historical data trend for Madrigal Pharmaceuticals's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Madrigal Pharmaceuticals Shiller PE Ratio Chart

Madrigal Pharmaceuticals Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Madrigal Pharmaceuticals Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Madrigal Pharmaceuticals's Shiller PE Ratio

For the Biotechnology subindustry, Madrigal Pharmaceuticals's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Madrigal Pharmaceuticals's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Madrigal Pharmaceuticals's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Madrigal Pharmaceuticals's Shiller PE Ratio falls into.


;
;

Madrigal Pharmaceuticals Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Madrigal Pharmaceuticals's E10 for the quarter that ended in Mar. 2025 is calculated as:

For example, Madrigal Pharmaceuticals's adjusted earnings per share data for the three months ended in Mar. 2025 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=-3.071/134.9266*134.9266
=-3.071

Current CPI (Mar. 2025) = 134.9266.

Madrigal Pharmaceuticals Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201506 -4.678 100.684 -6.269
201509 -9.320 100.392 -12.526
201512 -9.988 99.792 -13.505
201603 -8.729 100.470 -11.723
201606 -14.534 101.688 -19.285
201609 -1.417 101.861 -1.877
201612 -0.635 101.863 -0.841
201703 -0.467 102.862 -0.613
201706 -0.614 103.349 -0.802
201709 -0.571 104.136 -0.740
201712 -0.566 104.011 -0.734
201803 -0.365 105.290 -0.468
201806 -0.385 106.317 -0.489
201809 -0.480 106.507 -0.608
201812 -0.659 105.998 -0.839
201903 -0.867 107.251 -1.091
201906 -1.133 108.070 -1.415
201909 -1.262 108.329 -1.572
201912 -1.620 108.420 -2.016
202003 -2.118 108.902 -2.624
202006 -2.824 108.767 -3.503
202009 -3.184 109.815 -3.912
202012 -3.140 109.897 -3.855
202103 -2.789 111.754 -3.367
202106 -3.088 114.631 -3.635
202109 -3.222 115.734 -3.756
202112 -3.345 117.630 -3.837
202203 -3.051 121.301 -3.394
202206 -3.916 125.017 -4.226
202209 -4.798 125.227 -5.170
202212 -4.701 125.222 -5.065
202303 -3.951 127.348 -4.186
202306 -4.329 128.729 -4.537
202309 -5.004 129.860 -5.199
202312 -5.245 129.419 -5.468
202403 -6.790 131.776 -6.952
202406 -6.596 132.554 -6.714
202409 -4.433 133.029 -4.496
202412 -2.588 133.157 -2.622
202503 -3.071 134.927 -3.071

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Madrigal Pharmaceuticals  (FRA:YDO1) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Madrigal Pharmaceuticals Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Madrigal Pharmaceuticals's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Madrigal Pharmaceuticals Business Description

Traded in Other Exchanges
Address
200 Barr Harbor Drive, Suite 200, Four Tower Bridge, West Conshohocken, PA, USA, 19428
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH.

Madrigal Pharmaceuticals Headlines

No Headlines